We believe, to make a meaningful impact on treatment, it is necessary to have more than one drug or regimen. We therefore see combination therapies as…
In Conversation
Search by Country
Whether there is a pandemic or not, brain diseases don’t stop
I see a lot of growth opportunities in the Benelux, through global and local deals or partnerships
The greatest strength of Molcure’s system is the ability to discover drugs that could never be found by using conventional methods
There is growing interest from capital to invest in diagnostics companies. Within ten years, there is the possibility that this increased support and funding may help…
What is most important to stress is that there are many different applications for our technology, particularly in the field of regenerative medicine.
At Novartis, we do not shy away from competition. It is a good thing and it demonstrates the attractiveness of the market. There is a reason…
The key priority for my tenure is to create sustainability, both for Amgen and for biosimilars more generally within the global market.
I think that the COVID-19 crisis has certainly helped to bring the government and the industry closer together and we have seen a change in approach.…
We have a long-term ambition to accelerate prevention to halt the rise of diabetes, provide access to affordable care for vulnerable patients in every country and…
The most important element of any drug is whether it has a meaningful impact on patient outcomes. If you get that right, everything else takes care…
Since I joined in 2011, it feels as if my time with Sanofi Genzyme has been one constant, giant launch! ...the fundamental challenge but also opportunity…
